UAEM - Licensing and patenting practices of UK research institutions 2019-2020

Sarai Keestra made this Freedom of Information request to University of Aberdeen

Automatic anti-spam measures are in place for this older request. Please let us know if a further response is expected or if you are having trouble responding.

The request was successful.

Dear University of Aberdeen,

We have previously sent FOI requests asking for information about the licensing practices of UK universities. This was concerning the time period 18th October 2018 to 18th October 2019. We are now looking to update the information for the following year, 19th October 2019 to 19th October 2020.

The updated request is listed below:

For the purpose of clarity, please adhere to the following definitions when answering these questions:

Definitions
Low and middle income country: A country that is defined as ‘low’, ‘lower-middle’ and ‘upper-middle’ income by the World Bank for the year 2018. Income status defined by GNI per capita.
Source: World bank, available online [https://tinyurl.com/y5dwc2qv]

A patent grants an inventor the exclusive rights to his or her invention. A patent holder can stop other people from selling, manufacturing, producing, or using the invention for a certain period of time.
Source: Upcouncil, available online [https://www.upcounsel.com/what-is-a-pate...

Licence: Permission for the licensee to use the intellectual property rights
Source: TaylorWessing, available online [https://www.taylorwessing.com/download/a...

Exclusive Licence: A licence that allows only the named licensee to exploit the relevant IP rights, the licensor is also excluded from exploiting these IP rights.

Non-Exclusive Licence: A licence that grants any number of licensees to exploit the IP.
Source: TaylorWessing, available online [https://www.taylorwessing.com/synapse/co...

Health Technology: ‘Health technology as defined by the WHO: “A health technology is the application of organized knowledge and skills in the form of devices, medicines, vaccines, procedures and systems developed to solve a health problem and improve quality of lives.’
Source: WHO, available online [https://www.who.int/health-technology-as...

START FOI request:
Q1. Has the university committed to licensing its medical discoveries in ways that promote access and affordability in Low- and Middle- Income Countries? If yes, please provide a link or PDF to the relevant policy document.

Q2. Please provide an Excel spreadsheet with headings as displayed below with all the health technologies LICENSED by the university in the period 19th October 2019 to 19th October 2020 AND specify which countries they were licensed in AND specify whether they are exclusive or non-exclusive licenses.
Health Technology Licensed | Country of Licensing | Type of License (Exclusive or Non-Exclusive)

Q3. Please provide a list of patents granted to your organization in the period 19th October 2019 to 19th October 2020, listed by patent family, indicating countries/regions in which the patent has been granted.

Q4. In the period 19th October 2019 to 19th October 2020, has the university shared its best practices for promoting access to medicines through non-exclusive licensing by carrying out any of the following activities?

❏ Contributed sample clauses to the AUTM Global Health Toolkit
❏ Published an article, guidance, or other literature on access licensing practices
❏ Formally presented on access licensing practices at an academic or professional event, or at another university
❏ Informally shared or discussed access licensing practices with administrators at other universities
❏ Other
❏ None
(Tick as appropriate)

Q5. What actions has the technology transfer office (TTO) undertaken in the period 19th October 2019 to 19th October 2020 to improve access to the technologies they license in low-and middle-income settings?

END FOI request.
If you have any questions please do not hesitate to contact me by email.

Yours faithfully,

Sarai Keestra

Foi, University of Aberdeen

Dear Sarai Keestra,
I refer to your email of 31 October and, on behalf of the University, I acknowledge receipt and confirm that your request is being dealt with in terms of the Freedom of Information (Scotland) Act 2002. In terms of the Act, a reply will be sent to you as soon as possible and within the statutory timescales.

Yours sincerely,
Mary Sabiston
Information Compliance Officer
University of Aberdeen

show quoted sections

Foi, University of Aberdeen

1 Attachment

Dear Sarai Keestra,

FREEDOM OF INFORMATION REQUEST FOI 2020-334

I refer to your email of 31 October 2020 requesting information relating to Licensing and patenting practices, 2019/2020.

Your request has now been considered under the Freedom of Information (Scotland) Act 2002, ‘the Act’.

Q1. Has the university committed to licensing its medical discoveries in ways that promote access and affordability in Low- and Middle- Income Countries? If yes, please provide a link or PDF to the relevant policy document.

There is no policy.

Q2. Please provide an Excel spreadsheet with headings as displayed below with all the health technologies LICENSED by the university in the period 19th October 2019 to 19th October 2020 AND specify which countries they were licensed in AND specify whether they are exclusive or non-exclusive licenses.

Health Technology Licensed | Country of Licensing | Type of License (Exclusive or Non-Exclusive)

Please see the attached spreadsheet for the information you have requested.

Q3. Please provide a list of patents granted to your organization in the period 19th October 2019 to 19th October 2020, listed by patent family, indicating countries/regions in which the patent has been granted.

Thalidomide Analogs and Methods of Use
US patent 10,730,835 granted.

Q4. In the period 19th October 2019 to 19th October 2020, has the university shared its best practices for promoting access to medicines through non-exclusive licensing by carrying out any of the following activities?

❏ Contributed sample clauses to the AUTM Global Health Toolkit

❏ Published an article, guidance, or other literature on access licensing practices

❏ Formally presented on access licensing practices at an academic or professional event, or at another university

❏ Informally shared or discussed access licensing practices with administrators at other universities

❏ Other

❏✔ None

(Tick as appropriate)

Q5. What actions has the technology transfer office (TTO) undertaken in the period 19th October 2019 to 19th October 2020 to improve access to the technologies they license in low-and middle-income settings?
No actions were taken.

Where we have indicated that no information is held please accept this message as notice under section 17(1)(b) of the Act that the University does not hold any data.

Should you be dissatisfied with this response, you have the right to request a review. A request for review must be made within 40 working days of the receipt of this reply. It must include your name and address for correspondence and specify the request for information and the grounds for dissatisfaction with the decision. Please send your request for review to [University of Aberdeen request email].

If you are unhappy with the outcome of the University’s internal review, you have the right to appeal to the Scottish Information Commissioner within six months of the receipt of the University’s review response. Details on how to make an appeal to the Commissioner are available at www.itspublicknowledge.info/Appeal. Should you be dissatisfied with the Commissioner’s decision, you have a right of appeal to the Court of Session on a point of law.

Yours sincerely,
Mary Sabiston
Information Compliance Officer
University of Aberdeen

show quoted sections